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Abstract
Background: Fecal microbiota transplantation (FMT) has been shown to be safe and effective in treating refractory
or relapsing C. difficile infection (CDI), but its use has been limited by practical barriers. We recently reported a small
preliminary feasibility study using orally administered frozen fecal capsules. Following these early results, we now
report our clinical experience in a large cohort with structured follow-up.
Methods: We prospectively followed a cohort of patients with recurrent or refractory CDI who were treated with
frozen, encapsulated FMT at our institution. The primary endpoint was defined as clinical resolution whilst off
antibiotics for CDI at 8 weeks after last capsule ingestion. Safety was defined as any FMT-related adverse event
grade 2 or above.
Results: Overall, 180 patients aged 7–95 years with a minimal follow-up of 8 weeks were included in the analysis.
CDI resolved in 82 % of patients after a single treatment, rising to a 91 % cure rate with two treatments. Three
adverse events Grade 2 or above, deemed related or possibly related to FMT, were observed.
Conclusions: We confirm the effectiveness and safety of oral administration of frozen encapsulated fecal material,
prepared from unrelated donors, in treating recurrent CDI. Randomized studies and FMT registries are still needed
to ascertain long-term safety.
Keywords: Fecal microbiota transplant, Clostridium difficile, Microbiome, Oral administration
Background
The epidemiology of Clostridium difficile infection (CDI)
is evolving. Rates of infection are increasing and response
to standard antimicrobial treatment with metronidazole
or vancomycin may be suboptimal [1, 2]. Fidaxomicin has
been shown to reduce the rate of recurrence compared to
vancomycin; however, it has not been studied extensively
in patients with multiple recurrences, and use is limited
by cost [3]. Fecal microbiota transplant (FMT) has been
shown to be safe and effective in treating refractory or re-
lapsing CDI [4–8], but its use has been limited by practical
barriers. Among other concerns, the administration of
FMT by colonoscope or naso-gastric/duodenal tube ex-
poses the patient to some risk and discomfort. We re-
cently reported a preliminary feasibility study using orally
administered frozen fecal capsules, prepared from unre-
lated donors, to treat 20 patients with recurrent CDI [9].
Following these encouraging results, we have continued
treating patients with FMT capsules. We report our
clinical experience in a large cohort with structured
follow-up.
Methods
At the time of writing, 202 patients had been treated with
FMT capsules at Massachusetts General Hospital. The
outcomes of 180 patients who had completed an 8 week
follow-up assessment (with 154 completing follow-up/
reaching 6 months) are reported herein. Patients over the
age of 7 years, with three or more mild-to-moderate
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episodes of CDI or two episodes requiring hospitalization,
were offered capsule FMT. Absolute exclusions were
neutropenia (absolute neutrophil count < 500) and
prednisone > 40 mg/day; other immuno-suppressed
patients were considered with agreement of referring
physicians. The study was reviewed and approved by
the Partners Human Research Committee Institutional
Review Board and submitted to the Food and Drugs
Administration (IND 16011, sponsor E. Hohmann
MD). Recipients or parents provided written consent,
which discussed the risks, benefits, and investigational
nature of the procedure. Children provided assent. Donor
screening, preparation of the frozen capsules, FMT proce-
dures, and patient follow-up were unchanged from the
previous report [9]. Briefly, donors were healthy adults
with a normal body mass index, passed the American
Association of Blood Banks donor questionnaire, and
underwent physical examination and extensive laboratory
testing for general health and infectious diseases as
described [9].
Donated fecal matter was blenderized, sieved, centri-
fuged, and suspended in concentrated form in sterile
saline with 10 % glycerol. The suspension was double-
encapsulated in hypromellose capsules (Capsugel,
Cambridge, MA) and stored at –80 °C for up to
6 months pending use. Processing was done entirely
under ambient air. FMT recipients discontinued any
anti-CDI treatment for 24–48 hours prior to FMT, and
were given 15 capsules on each of two consecutive
days with water or apple sauce. The 30 capsules con-
tained sieved, concentrated material derived from a
mean of 48 g of fecal matter. Recipients were nil per os
4 hours before and 1 hour after dosing. Those with
worsening diarrheal symptoms at least 72 hours after
the second dosing day had fecal samples retested for C.
difficile. If they had diarrhea and still tested positive,
they were retreated with 4–14 days of standard anti-
biotic therapy for CDI and were offered another FMT.
Patients were followed on a standardized schedule by
phone (3–5 days, 10–14 days, 2 months, and 6 months
after FMT) with structured questionnaires recording
stool frequency, general and gastrointestinal well-
being, and mild, moderate, or severe adverse events
(grades 1, 2, or 3 based upon CTCAE V.4.0). The pri-
mary endpoint was defined as clinical resolution/no re-
lapse of diarrhea whilst off antibiotics for CDI at
8 weeks after last capsule ingestion and safety, defined
as any FMT-related adverse events grade 2 or above.
Resolution of diarrhea was defined as three or fewer
bowel movements per 24 hours. For brevity going for-
ward we have defined this resolution as a “cure”
though we appreciate “resolution of symptoms/no re-
lapse” may be preferred. Fecal microbiome analyses
were beyond the scope of this treatment study.
Results
From July 2013 through April 2016, 180 patients aged 7–
95 years (median 64) were treated using fecal material col-
lected from seven donors; 82 recipients were over 65 years
old, whereas five were < 18 years and 15 were > 85 years.
Cure rates and adverse events (to 6 months) are shown
in Fig. 1. Of the 180 patients reaching 8 weeks, 147
were cured of CDI after the first administration of fecal
capsules (82 %). Twenty six individuals relapsed within
8 weeks and were re-treated, with 17 responding,
resulting in an overall cure rate of 91 % with one or
two treatments. Six individuals declined re-treatment
(our standard procedure in these cases is to offer long-
term suppressive oral vancomycin treatment). Three
patients were cured after a third administration, but
were considered “non-responders” as per protocol def-
inition. One patient received three treatments, relapsed,
and was advised to continue suppressive vancomycin.
Fig. 1 Cure rates and cumulative adverse events in 180 capsule fecal
microbiota transplant recipients. All recipients were followed for 8
weeks, and 154 completed 6 months of follow-up
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Five patients relapsed in the 2–6 month window, one
due to antibiotic treatment, one due to chemotherapy,
and three spontaneously. Four patients were retreated
and one was lost to follow-up. Of the four patients
retreated, all durably resolved, but one died of recur-
rent cancer.
Only three serious adverse events Grade 2 or above
(one transient high fever, two new endoscopic diagno-
ses of ulcerative colitis) deemed related or possibly re-
lated to FMT were observed. Two patients who had
ongoing, worsening diarrheal symptoms after FMT
were found by colonoscopy with biopsy to have ulcera-
tive colitis, which was previously suspected in one.
Fourteen patients died within the 6 month follow-up
window; no deaths were deemed related to FMT by ei-
ther the FMT team or by referring/treating physicians.
Six patients (3 %) were re-hospitalized for relapsed
CDI; other hospitalizations were for other/underlying
conditions. Two patients experienced small bowel ob-
structions after FMT. One was admitted with a partial
small bowel obstruction 8 weeks after FMT (his fifth
episode of bowel obstruction in the past 18 months).
This resolved with conservative management and was
believed related to past abdominal surgeries. Another
patient with rheumatological disease and past immuno-
modulatory therapy had a small bowel obstruction
4 weeks and 12 weeks after two FMT treatments, re-
spectively. This patient required surgery, which re-
vealed a chronic inflammatory mass, attributed by the
surgeon to complications of an adhesion or an umbil-
ical hernia which led to perforation and contained ab-
scess formation. A single patient with a history of
emesis after taking oral medications vomited up 15 in-
tact capsules immediately after ingestion of his second
day’s dose, but was cured of CDI. Five patients experi-
enced vomiting 6 to 9 hours after the initial 15 cap-
sules, and did not bring up any capsules – all but one
of these five took a second treatment with 15 capsules,
did not vomit, and had resolved CDI; one declined and
relapsed. Four patients had transient low grade fever.
Mild transient gastrointestinal adverse events included
post-treatment diarrhea, nausea, abdominal discomfort
and bloating, and were reported in the majority of
patients (Fig. 1). Seven patients relapsed with CDI
between 8 weeks and 6 months, four without obvious
precipitant, one each possibly related to antibiotics,
chemotherapy, or prednisone treatments. There was no
documented or suspected transmission of infection. Three
patients on suppressive oral antibiotics (ciprofloxacin,
nitrofurantoin, trimethoprim/sulfamethoxazole) that were
deemed necessary by their infectious disease physicians,
and viewed as exclusionary by other FMT providers, were
treated with FMT while on these drugs, and all were cured
of CDI at 8 weeks.
Discussion
Herein, we confirm the effectiveness and safety of oral
administration of frozen encapsulated fecal material,
from unrelated donors, in treating recurrent CDI, with
an overall “cure” rate, defined as resolution/no relapse of
diarrhea at 8 weeks, of 91 % with one or two administra-
tions of 30 capsules. This compares favorably to rates re-
ported for colonoscopic administration, which are in the
range of 93 to 96 % [5]. Flare or unmasking of inflamma-
tory bowel disease is a reported complication of both
FMT and CDI, and occurred in two patients here. The
majority of patients reported mild gastrointestinal com-
plaints after FMT, which resolved without intervention.
We use a standardized grading system for adverse events,
and about 84 % of reported events were Grade 1 (symp-
toms causing no or minimal interference with usual social
and functional activities). Death and hospitalization rates
reflect the co-morbidities of this patient population.
Recent case reports have highlighted rare adverse out-
comes after FMT [10, 11]. In both reports, it seems the in-
vasive procedure performed to administer the inoculum
may have been a contributing factor. The use of capsules
obviates the need for any invasive procedures, potentially
overcoming procedure-associated risks.
FMT has been shown to be the most cost-effective
treatment strategy for recurrent CDI, when compared to
vancomycin or fidaxomicin [12]. Greatly simplifying de-
livery and reducing the person-power and infrastructure
required, oral administration is likely to make FMT even
more favorable in terms of cost–benefit. Resolution of
recurrent CDI in patients in acute and long-term care
facilities may confer an additional health system and so-
cietal benefit by reducing transmission. Nevertheless,
some potential limitations of oral administration of FMT
should be kept in mind. The use of capsules requires the
patients’ cooperation and is limited in patients with
dysphagia or gastrointestinal dysmotility. Vomiting and
aspiration remain a potential concern, though in our
experience, it is a rare occurrence. While the administra-
tion is greatly simplified, preparation of capsules is
labor-intensive compared to inocula intended for endo-
scopic administration, and might not be feasible in some
clinical settings.
The main strength of this study lies in our sample
size and structured follow-up. We acknowledge a lack
of placebo or active comparator; we note that placebo
administration is challenging in patients with multiple
episodes of CDI or hospital admissions. Reasons for re-
lapse after FMT would be interesting to characterize
from a microbiome perspective.
Conclusion
Capsule FMT is now offered as standard care for recur-
rent or refractory CDI at Massachusetts General Hospital.
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Nevertheless, long-term safety concerns remain an im-
portant issue, especially in younger patients. Transmission
of infections and complications related to microbiome
manipulation are also potential concerns. Therefore, larger
studies and FMT registries will be of value.
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